# Bafna Pharmaceuticals share price today (Bafna Pharmaceuticals Ltd, NSE: BAFNAPH)

> Bafna Pharmaceuticals share price today: ₹430.20 at the NSE close on 3 November 2026. Bafna Pharmaceuticals (NSE: BAFNAPH) is worth ₹1,018 crore and trades at a P/E of 130.6. > Bafna Pharmaceuticals Ltd's share price, valuation and earnings point in different directions. The next one or two quarters should make it clearer. BAFNAPH · Pharma - Formulators · data as of 3 November 2026. Page: https://www.sectoralpha.in/stocks/bafna-pharmaceuticals-ltd

Sector Alpha also publishes a daily newsletter that explains one Indian stock at a time: https://newsletter.sectoralpha.in/?utm_source=sectoralpha&utm_medium=ai_text&utm_campaign=llms

## Key numbers

- Business trend: Mixed, from fewer quarters than usual
- Price: ₹430.20
- P/E: 130.6× (higher than 87% of the last 8.7 years)
- Revenue (Jun 2026): ₹26.6 Cr (−23.2% on a year ago)
- Profit (Jun 2026): ₹0.1 Cr (−97.6% on a year ago)
- Operating margin: 3.4% (−11.3 points on a year ago)
- ROCE: 12%, FY26
- ROIC: 4.0%, against a 12.0% cost of capital: −8.0 points

The main question: foreign institutions moved +9.3 percentage points over 8 quarters while the business went the other way. ## What is the Bafna Pharmaceuticals share price today? Bafna Pharmaceuticals Ltd's share price was ₹430.20 at the close on 3 November 2026. It has been rising for 25 weeks. That is 75.9% above its average price over the last 200 trading days. Over the past 13 weeks it has done better than the NIFTY 500, and it has stayed ahead for 12 weeks in a row. Since its first close in our records, on 29 May 2026, it has traded between ₹132 and ₹461, and at that close it sat 91% of the way up from that low. Over the last 5 months the share price moved +226% while the NIFTY 500 moved −3%, so it is ahead of the index over that whole period. The chart above shows the 13-week comparison for every week. This page treats a rise as over when the price closes below its 200-day average on two Fridays in a row. ## What changed at Bafna Pharmaceuticals this quarter? Three changes stood out: profit fell in the June 2026 quarter, revenue fell in the June 2026 quarter and lowest operating margin in 10 quarters. 1. Profit fell in the June 2026 quarter Profit was ₹0 crore, -97.6% on a year earlier (₹3 crore), after 4 quarters of growth. 2. Revenue fell in the June 2026 quarter Revenue was ₹27 crore, -23.2% on a year earlier (₹35 crore), after 2 quarters of growth. 3. Lowest operating margin in 10 quarters Operating margin was 3.4% in the June 2026 quarter, against 14.6% a year earlier. ## What are Bafna Pharmaceuticals' latest quarterly results? For April to June 2026 (the quarter ended 30 June 2026), Bafna Pharmaceuticals reported revenue of ₹26.6 crore, down 23.2% from ₹34.6 crore a year earlier, and a profit of ₹0.08 crore, down 97.6% from ₹3.39 crore. ### Bafna Pharmaceuticals results: April to June 2026 against a year earlier

| Measure | April to June 2026 | April to June 2025 | Change |
| --- | --- | --- | --- |
| Revenue | ₹26.6 crore | ₹34.6 crore | −23.2% |
| Profit | ₹0.08 crore | ₹3.39 crore | −97.6% |
| Earnings per share | ₹0.03 | ₹1.43 | −97.9% |
| Operating margin | 3.4% | 14.6% | −11.3 points |

The next results, for July to September 2026, are due by 14 November 2026: listed companies must publish quarterly results within 45 days of the quarter's end (60 days for the January to March quarter). (From the company's reported quarterly results (quarter ended 30 June 2026). Revenue and profit in ₹ crore.)

## What is the Bafna Pharmaceuticals share price history? Bafna Pharmaceuticals closed at ₹430.20 on 3 November 2026. Its highest weekly close since May 2026 was ₹461.35 on 16 October 2026. ### Bafna Pharmaceuticals share price: then and now

| When | Close | Change to 3 Nov 2026 |
| --- | --- | --- |
| 1 week ago · 23 Oct 2026 | ₹442.95 | −2.9% |
| 1 month ago · 1 Oct 2026 | ₹378.75 | +13.6% |
| Earliest and lowest weekly close in our records · 29 May 2026 | ₹131.90 | +226.2% |
| Highest weekly close since May 2026 · 16 Oct 2026 | ₹461.35 | −6.8% |

Weekly closing prices. Each change is the move from that price to the 3 Nov 2026 close. A day's intraday high or low can go beyond these weekly closes. (25 weekly closes from 29 May 2026 to 3 November 2026.)

## What is the latest news on Bafna Pharmaceuticals? 3 Nov 2026: Bafna Pharmaceuticals closed at ₹430.20, down 2.9% on the week and up 13.6% on the month. Results for April to June 2026: Revenue down 23.2% and profit down 97.6% on a year earlier. ## What dividend does Bafna Pharmaceuticals pay? Bafna Pharmaceuticals has paid no dividend on the NSE since its first NSE close in our records (29 May 2026), the start of the period we checked. Not in its latest year. Bafna Pharmaceuticals Ltd paid out 0% of its profit as dividends in FY26. It did pay a dividend in 1 of its last 15 reported years, so there is a history but no current dividend. (From the NSE corporate-actions record, read 4 November 2026.)

## Which stock lists is Bafna Pharmaceuticals on? Bafna Pharmaceuticals is on 2 of our India lists: Momentum stocks and Pharma stocks. - [Momentum stocks Market cap cr: 1038.8189327974994](https://www.sectoralpha.in/momentum-stocks-india)
- [Pharma stocks Market value (₹ crore): 1038.8189327974994](https://www.sectoralpha.in/sectors/pharma-stocks-india)

## Is Bafna Pharmaceuticals profitable? Bafna Pharmaceuticals Ltd earned ₹0.1 Cr of net profit in the Jun 2026 quarter, −97.6% on the same quarter a year earlier. Full-year FY26 profit was ₹11.0 Cr. That is 0.3% of the quarter's revenue. The same quarter a year earlier earned ₹3.4 Cr. 2 of the last 12 reported quarters were loss-making. For the full year, FY26 profit was ₹11.0 Cr (+175.0% on the year before). Why profit moved: revenue changed −23.2% on a year earlier and the margin moved −11.3 percentage points. Sales did the work while the margin got thinner. On average over the last four quarters, profit changed +31.3% and revenue −2.9%. Profit is growing faster than sales: fixed costs are spread over more sales, so each extra rupee of revenue adds more to profit. ## How much revenue does Bafna Pharmaceuticals make, and is it growing? Bafna Pharmaceuticals Ltd reported ₹26.6 Cr of revenue in the Jun 2026 quarter, −23.2% on the same quarter a year earlier. Over 10 years it has grown 5.9% a year on average. The last full year, FY26, came in at ₹151 Cr. The last four reported quarters add to ₹143 Cr. FY26 revenue was ₹151 Cr, +3.4% on the year before. Recent pace: the last four quarters grew −2.9% on average, against 5.9% a year over the longer run, so this year is growing slower than its own long-run rate. Is growth speeding up? Revenue over the last 12 months grew −3.1%, against −0.4% a year over the last 8 quarters (stabilising); profit over the last 12 months grew −5.8%, against +427.5% a year (rolling over). ## How much of every ₹100 of sales does Bafna Pharmaceuticals keep? Bafna Pharmaceuticals Ltd's operating margin was 3.4% in the Jun 2026 quarter, 11.3 percentage points lower than the same quarter a year ago. Across 15 years it has been between −77.0% and 15.0%. The latest quarter is within that range. Why the margin moved: operating margin changed −11.3 percentage points on the year while gross margin changed +2.6 points. So the drop came mostly from costs below the gross margin, such as staff and overheads, measured against sales. ## Is Bafna Pharmaceuticals' profit turning into cash? Over the last 3 years, 209% of Bafna Pharmaceuticals Ltd's reported profit came in as cash from its operations, so the profit is backed by cash. In FY26 it brought in ₹15.0 Cr of operating cash against ₹11.0 Cr of profit. After ₹25.0 Cr of spending on assets, free cash was −₹10.0 Cr: it spent more than its operations brought in. Cash-flow figures here are yearly, because quarterly cash statements are not published, so this section changes once a year. Why 209% of profit came in as cash: the cash cycle stayed about the same between FY21 and FY26, so the cash follows profit, not the cycle. What to look at next: the bigger use of cash is spending on new assets, at 3.7× depreciation over three years. The next section checks what that spending is building. ## Where does Bafna Pharmaceuticals' cash go? Bafna Pharmaceuticals Ltd's cash cycle, the days between paying suppliers and getting paid by customers, was 96 days in FY26, down from 96 days in FY21. It spent ₹59.0 Cr on assets over the last 3 years. Customers take 106 days to pay, and stock sits for 129 days on average. At FY26 sales of ₹151 Cr, each day of that cycle ties up about ₹0.4 Cr, so roughly ₹40.0 Cr is tied up in the business at any time. FY26: customers took 106 days to pay and stock sat for 129 days, about 4.2 months of sales sitting as stock, for a full cycle of 96 days, shorter than FY21's 96. The full loop: cash goes out to suppliers and production on day 0. Stock sits for 129 days. Customers pay about 106 days after that. Suppliers are paid at 139 days. Together that makes the 96-day cycle. Spending on assets: ₹59.0 Cr over the last 3 years, against ₹16.0 Cr of depreciation (the yearly wear and tear on existing assets). So it is building well beyond replacing what wears out. Work still in progress is ₹3.0 Cr (FY26): assets paid for that are not earning yet. In short: the cash is going into new capacity, not getting stuck in the daily cycle. The question is whether the new capacity earns. ## What is Bafna Pharmaceuticals' P/E ratio, and how does it compare with its own history? Bafna Pharmaceuticals Ltd's P/E is 130.6×, near the high end of its own history: higher than 87% of past readings. Its usual P/E (the middle reading) is 40.5×, over 8.7 years of weekly prices. This compares the share price with the company’s own past. It does not say what the business is worth. In short: the multiple is high against its own past, so the earnings trend underneath matters more than the multiple. ## Is the Bafna Pharmaceuticals business getting better or worse? Bafna Pharmaceuticals Ltd's business is giving mixed signals. There is no clear direction across the growth lines, with ROCE steady at 10.3%; each line tells part of the story. This is based on 12 quarters of 3 measures, with some gaps. Why it matters: when the lines disagree, each line above matters more than any single label. This reading has some gaps: at least one line is short, or the return line is not the quarterly series, so treat it with a little more caution. ## How much does Bafna Pharmaceuticals earn on its capital? Bafna Pharmaceuticals Ltd earned a ROCE of 12% in FY26. That is up from a low of −35% in FY18. Its return on capital used (ROIC) is 8.0 percentage points below its cost of capital, so growth here does not yet pay for the capital it uses. It comes from a 7.3% net margin and 0.86× asset turnover (sales divided by assets). Why the return is what it is (FY26): a 7.3% net margin × 0.86× asset turnover × 1.83× leverage (assets divided by equity) ≈ 11.5% on equity. The margin does its share; borrowing is a big part of it. The key test, return on capital used minus the cost of capital: 4.0% − 12.0% = −8.0 percentage points. The 12.0% is a standard assumption for the cost of capital in India, not an estimate for this company. Read the sign and size of the gap, not the decimals. Negative: growth at these returns loses value until returns improve. The 4.0% ROIC above is the latest reading, as reported. The yearly chart below shows FY26 at 8.8%, and the quarterly chart works out each 12-month window from the quarterly figures, so the readings differ by date, not by method. ## Does Bafna Pharmaceuticals have too much debt? Bafna Pharmaceuticals Ltd has total debt of ₹37.0 Cr against shareholder equity of ₹96.0 Cr as of Jun 2026, so its debt is 0.39× its equity. Year by year, that ratio went from 0.18 in FY22 to 0.39 in FY26. Keep that borrowing in mind when reading the returns on this page. ## What is the Bafna Pharmaceuticals shareholding pattern? Promoters cut their stake in Bafna Pharmaceuticals Ltd by 13.3 percentage points over 8 quarters, the biggest change among its owners. Promoters now own 75.0% of the company. Foreign institutions moved +9.3 points over the same period, to 9.3%. This uses the four owner groups that companies report every quarter; nothing is guessed between filings. Why the owners changed: promoters drove it (−13.3 points), with the other side taken by foreign institutions (+9.3 points). They reduced their stake. ## How far is Bafna Pharmaceuticals from balance-sheet trouble? For Bafna Pharmaceuticals Ltd, the Z-score is not available, so we say so rather than guess one. It estimates how far the balance sheet is from trouble; it is not a forecast of failure. The debt, cash-flow and return sections show the balance-sheet figures we do have, each with its own date. ## How does Bafna Pharmaceuticals rank in its industry? 35.8 out of 100, rank 36 of 44 in Pharma - Formulators, with 74% of the evidence available. Bafna Pharmaceuticals Ltd scores 35.8 out of 100 against the 44 companies it is compared with in Pharma - Formulators, ranking 36. The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. The four parts add up to the total exactly: 7.1 + 5.4 + 10.8 + 12.5 = 35.8. This is the same number shown on the industry page; it is worked out once for the whole group and read here. What would change it: The score would fall if profit growth turns negative or margins stop improving while the share price lags its sector. ## Which companies is Bafna Pharmaceuticals compared with? Bafna Pharmaceuticals ranks 36 of 44 Pharma - Formulators companies on the 4-Factor Sector Score, with 35.8 out of 100. 1. [Rubicon Research Ltd](https://www.sectoralpha.in/stocks/rubicon-research-ltd) RUBICON · leader · Most evidence points up · 83% evidence 71.4 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 30.1/35 · Revenue 46.8% · Profit 91.4% · Operating margin change 2 points · 88% evidence Capital efficiency 18.6/25 · ROCE 28.4% · Operating margin 24% · 100% evidence Valuation 6.2/20 · P/E 92.5× · PEG 2.31 · 65% evidence Relative strength 16.5/20 · Lead over its industry 28.1% · Lead over NIFTY 500 53.6% · 1 year 160.5% · 70% evidence · 11 of 12 weeks ahead Exact sum: 30.1 + 18.6 + 6.2 + 16.5 = 71.4 · What this means: Earnings, capital efficiency and relative strength all agree. The open questions are about management, upcoming events and risks. 2. [Kwality Pharmaceuticals Ltd](https://www.sectoralpha.in/stocks/kwality-pharmaceuticals-ltd) KPL · breaking out · Most evidence points up · 81% evidence 71.4 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 29.9/35 · Revenue 37.9% · Profit 88.4% · Operating margin change 3 points · 88% evidence Capital efficiency 18.2/25 · ROCE 24.1% · Operating margin 25% · 100% evidence Valuation 11.0/20 · P/E 44.2× · PEG 0.54 · 100% evidence Relative strength 12.3/20 · Lead over its industry n/a · Lead over NIFTY 500 74.4% · 1 year 288.9% · 25% evidence · 9 of 9 weeks ahead Exact sum: 29.9 + 18.2 + 11 + 12.3 = 71.4 · What this means: Earnings, capital efficiency and relative strength all agree. The open questions are about management, upcoming events and risks. 3. [Accent Microcell Ltd](https://www.sectoralpha.in/stocks/accent-microcell-ltd) ACCENTMIC · leader · Most evidence points up · 65% evidence 70.5 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 21.4/35 · Revenue n/a · Profit n/a · Operating margin change 7 points · 27% evidence Capital efficiency 21.4/25 · ROCE 24.9% · Operating margin 24% · 100% evidence Valuation 9.1/20 · P/E 26.9× · PEG n/a · 50% evidence Relative strength 18.6/20 · Lead over its industry 21.4% · Lead over NIFTY 500 47.6% · 1 year 132.1% · 100% evidence · 12 of 12 weeks ahead Exact sum: 21.4 + 21.4 + 9.1 + 18.6 = 70.5 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 4. [Ajanta Pharma Ltd](https://www.sectoralpha.in/stocks/ajanta-pharma-ltd) AJANTPHARM · leader · Most evidence points up · 100% evidence 69.2 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 30.3/35 · Revenue 25% · Profit 29.8% · Operating margin change 7 points · 100% evidence Capital efficiency 21.3/25 · ROCE 34.5% · Operating margin 31% · 100% evidence Valuation 7.1/20 · P/E 34.7× · PEG 1.77 · 100% evidence Relative strength 10.5/20 · Lead over its industry -3.5% · Lead over NIFTY 500 20% · 1 year 42.3% · 100% evidence · 11 of 12 weeks ahead Exact sum: 30.3 + 21.3 + 7.1 + 10.5 = 69.2 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 5. [Glenmark Pharmaceuticals Ltd](https://www.sectoralpha.in/stocks/glenmark-pharmaceuticals-ltd) GLENMARK · breaking out · Most evidence points up · 86% evidence 69.2 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 29.1/35 · Revenue 32.9% · Profit 100% · Operating margin change 2 points · 88% evidence Capital efficiency 20.3/25 · ROCE 39.8% · Operating margin 20% · 100% evidence Valuation 11.2/20 · P/E 20.8× · PEG n/a · 50% evidence Relative strength 8.6/20 · Lead over its industry -11.4% · Lead over NIFTY 500 10.8% · 1 year 21.5% · 100% evidence · 9 of 12 weeks ahead Exact sum: 29.1 + 20.3 + 11.2 + 8.6 = 69.2 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 6. [Bliss GVS Pharma Ltd](https://www.sectoralpha.in/stocks/bliss-gvs-pharma-ltd) BLISSGVS · leader · Most evidence points up · 82% evidence 67.1 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 29.3/35 · Revenue 25% · Profit 43.1% · Operating margin change 8 points · 95% evidence Capital efficiency 14.7/25 · ROCE 16.9% · Operating margin 26% · 76% evidence Valuation 6.4/20 · P/E 42.4× · PEG n/a · 50% evidence Relative strength 16.7/20 · Lead over its industry 59% · Lead over NIFTY 500 86.2% · 1 year 312.8% · 100% evidence · 12 of 12 weeks ahead Exact sum: 29.3 + 14.7 + 6.4 + 16.7 = 67.1 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 7. [Fredun Pharmaceuticals Ltd](https://www.sectoralpha.in/stocks/fredun-pharmaceuticals-ltd) FREDUN · breaking out · Most evidence points up · 76% evidence 65.8 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 31.9/43.75 · Revenue 50.3% · Profit 91.3% · Operating margin change 0 points · 88% evidence Capital efficiency 19.0/31.25 · ROCE 21.5% · Operating margin 14% · 100% evidence Valuation 14.9/25 · P/E 52.7× · PEG 0.77 · 100% evidence Relative strength: no reading this week · its 20 points are shared across the other three Exact sum: 31.9 + 19 + 14.9 = 65.8 (no relative-strength reading this week; its 20 points are shared across the other three) · What this means: There is no relative-strength reading for this week, so the score is built from earnings, capital efficiency and valuation alone. 8. [Lupin Ltd](https://www.sectoralpha.in/stocks/lupin-ltd) LUPIN · quiet · Most evidence points up · 89% evidence 65.4 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 27.9/35 · Revenue 28.2% · Profit 49.2% · Operating margin change 2 points · 88% evidence Capital efficiency 19.4/25 · ROCE 29.9% · Operating margin 30% · 100% evidence Valuation 16.1/20 · P/E 15.4× · PEG 0.54 · 65% evidence Relative strength 2.0/20 · Lead over its industry -24.5% · Lead over NIFTY 500 -4.7% · 1 year 2.4% · 100% evidence · 0 of 12 weeks ahead Exact sum: 27.9 + 19.4 + 16.1 + 2 = 65.4 · What this means: Earnings are strong; relative strength in its sector is -24.5% and the one-year return is 2.4%. 9. [Ipca Laboratories Ltd](https://www.sectoralpha.in/stocks/ipca-laboratories-ltd) IPCALAB · turning · Most evidence points up · 78% evidence 65.4 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 24.0/35 · Revenue 10.6% · Profit 68% · Operating margin change 6 points · 83% evidence Capital efficiency 15.7/25 · ROCE 17% · Operating margin 24% · 76% evidence Valuation 11.0/20 · P/E 35.6× · PEG n/a · 50% evidence Relative strength 14.7/20 · Lead over its industry -0.5% · Lead over NIFTY 500 23.6% · 1 year 51.7% · 100% evidence · 10 of 12 weeks ahead Exact sum: 24 + 15.7 + 11 + 14.7 = 65.4 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 10. [Marksans Pharma Ltd](https://www.sectoralpha.in/stocks/marksans-pharma-ltd) MARKSANS · leader · Evidence leans up · 74% evidence 64.1 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 28.7/35 · Revenue 19.6% · Profit 48% · Operating margin change 9 points · 88% evidence Capital efficiency 17.2/25 · ROCE 18.8% · Operating margin 25% · 100% evidence Valuation 6.3/20 · P/E 26.8× · PEG 2.85 · 65% evidence Relative strength 11.9/20 · Lead over its industry n/a · Lead over NIFTY 500 40.1% · 1 year 68.4% · 25% evidence · 12 of 12 weeks ahead Exact sum: 28.7 + 17.2 + 6.3 + 11.9 = 64.1 · What this means: Earnings, capital efficiency and relative strength all agree. The open questions are about management, upcoming events and risks. 11. [FDC Ltd](https://www.sectoralpha.in/stocks/fdc-ltd) FDC · basing · Evidence leans up · 85% evidence 62.8 out of 100 Growth Capital Valuation Relative
12. [Corona Remedies Ltd](https://www.sectoralpha.in/stocks/corona-remedies-ltd) CORONA · turning · Evidence leans up · 73% evidence 62.5 out of 100 Growth Capital Valuation Relative
13. [Emcure Pharmaceuticals Ltd](https://www.sectoralpha.in/stocks/emcure-pharmaceuticals-ltd) EMCURE · losing its lead · Evidence leans up · 71% evidence 61.8 out of 100 Growth Capital Valuation Relative
14. [Mankind Pharma Ltd](https://www.sectoralpha.in/stocks/mankind-pharma-ltd) MANKIND · turning · Evidence leans up · 100% evidence 61.0 out of 100 Growth Capital Valuation Relative
15. [Zydus Lifesciences Ltd](https://www.sectoralpha.in/stocks/zydus-lifesciences-ltd) ZYDUSLIFE · leader · Evidence leans up · 96% evidence 58.1 out of 100 Growth Capital Valuation Relative
16. [Gufic BioSciences Ltd](https://www.sectoralpha.in/stocks/gufic-biosciences-ltd) GUFICBIO · leader · Evidence leans up · 71% evidence 56.2 out of 100 Growth Capital Valuation Relative
17. [ERIS Lifesciences Ltd](https://www.sectoralpha.in/stocks/eris-lifesciences-ltd) ERIS · basing · Evidence leans up · 67% evidence 56.1 out of 100 Growth Capital Valuation Relative
18. [Strides Pharma Science Ltd](https://www.sectoralpha.in/stocks/strides-pharma-science-ltd) STAR · breaking out · Evidence leans up · 75% evidence 55.3 out of 100 Growth Capital Valuation Relative
19. [Caplin Point Laboratories Ltd](https://www.sectoralpha.in/stocks/caplin-point-laboratories-ltd) CAPLIPOINT · losing its lead · Evidence leans up · 96% evidence 54.3 out of 100 Growth Capital Valuation Relative
20. [Wockhardt Ltd](https://www.sectoralpha.in/stocks/wockhardt-ltd) WOCKPHARMA · losing its lead · Evidence leans up · 71% evidence 52.8 out of 100 Growth Capital Valuation Relative
21. [Kilitch Drugs (India) Ltd](https://www.sectoralpha.in/stocks/kilitch-drugs-indialtd) KILITCH · breaking out · Evidence leans up · 78% evidence 51.3 out of 100 Growth Capital Valuation Relative
22. [Akums Drugs & Pharmaceuticals Ltd](https://www.sectoralpha.in/stocks/akums-drugs-pharmaceuticals-ltd) AKUMS · leader · Evidence leans up · 71% evidence 50.9 out of 100 Growth Capital Valuation Relative
23. [Alkem Laboratories Ltd](https://www.sectoralpha.in/stocks/alkem-laboratories-ltd) ALKEM · quiet · Evidence leans down · 78% evidence 47.6 out of 100 Growth Capital Valuation Relative
24. [Alembic Pharmaceuticals Ltd](https://www.sectoralpha.in/stocks/alembic-pharmaceuticals-ltd) APLLTD · turning · Evidence leans down · 81% evidence 46.9 out of 100 Growth Capital Valuation Relative
25. [Bajaj Healthcare Ltd](https://www.sectoralpha.in/stocks/bajaj-healthcare-ltd) BAJAJHCARE · quiet · Evidence leans down · 100% evidence 46.5 out of 100 Growth Capital Valuation Relative
26. [Lincoln Pharmaceuticals Ltd](https://www.sectoralpha.in/stocks/lincoln-pharmaceuticals-ltd) LINCOLN · quiet · Evidence leans down · 100% evidence 46.0 out of 100 Growth Capital Valuation Relative
27. [Bharat Parenterals Ltd](https://www.sectoralpha.in/stocks/bharat-parenterals-ltd) BPLPHARMA · breaking out · Too little evidence to rank firmly · 52% evidence 45.9 out of 100 Growth Capital Valuation Relative
28. [Aurobindo Pharma Ltd](https://www.sectoralpha.in/stocks/aurobindo-pharma-ltd) AUROPHARMA · leader · Evidence leans down · 96% evidence 45.7 out of 100 Growth Capital Valuation Relative
29. [Amrutanjan Health Care Ltd](https://www.sectoralpha.in/stocks/amrutanjan-health-care-ltd) AMRUTANJAN · turning · Evidence leans down · 96% evidence 44.9 out of 100 Growth Capital Valuation Relative
30. [RPG Life Sciences Ltd](https://www.sectoralpha.in/stocks/rpg-life-sciences-ltd) RPGLIFE · losing its lead · Evidence leans down · 100% evidence 43.1 out of 100 Growth Capital Valuation Relative
31. [J B Chemicals & Pharmaceuticals Ltd](https://www.sectoralpha.in/stocks/j-b-chemicals-pharmaceuticals-ltd) JBCHEPHARM · Too little evidence to rank firmly · 59% evidence 42.6 out of 100 Growth Capital Valuation Relative
32. [Zim Laboratories Ltd](https://www.sectoralpha.in/stocks/zim-laboratories-ltd) ZIMLAB · leader · Evidence leans down · 71% evidence 42.2 out of 100 Growth Capital Valuation Relative
33. [Sun Pharmaceutical Industries Ltd](https://www.sectoralpha.in/stocks/sun-pharmaceutical-industries-ltd) SUNPHARMA · quiet · Evidence leans down · 100% evidence 39.4 out of 100 Growth Capital Valuation Relative
34. [Dr Reddys Laboratories Ltd](https://www.sectoralpha.in/stocks/dr-reddys-laboratories-ltd) DRREDDY · turning · Evidence leans down · 100% evidence 39.4 out of 100 Growth Capital Valuation Relative
35. [Natco Pharma Ltd](https://www.sectoralpha.in/stocks/natco-pharma-ltd) NATCOPHARM · quiet · Evidence leans down · 96% evidence 38.8 out of 100 Growth Capital Valuation Relative
36. Bafna Pharmaceuticals Ltd this page BAFNAPH · breaking out · Evidence leans down · 74% evidence 35.8 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 7.1/35 · Revenue -3.1% · Profit -5.8% · Operating margin change -11.3 points · 88% evidence Capital efficiency 5.4/25 · ROCE 11.9% · Operating margin 3.4% · 100% evidence Valuation 10.8/20 · P/E 136× · PEG 1.16 · 65% evidence Relative strength 12.5/20 · Lead over its industry n/a · Lead over NIFTY 500 134.4% · 1 year n/a · 25% evidence · 10 of 10 weeks ahead Exact sum: 7.1 + 5.4 + 10.8 + 12.5 = 35.8 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 37. [Cipla Ltd](https://www.sectoralpha.in/stocks/cipla-ltd) CIPLA · turning · Evidence leans down · 100% evidence 35.4 out of 100 Growth Capital Valuation Relative
38. [Torrent Pharmaceuticals Ltd](https://www.sectoralpha.in/stocks/torrent-pharmaceuticals-ltd) TORNTPHARM · losing its lead · Most evidence points down · 100% evidence 34.6 out of 100 Growth Capital Valuation Relative
39. [Biocon Ltd](https://www.sectoralpha.in/stocks/biocon-ltd) BIOCON · quiet · Most evidence points down · 96% evidence 34.4 out of 100 Growth Capital Valuation Relative
40. [Suven Life Sciences Ltd](https://www.sectoralpha.in/stocks/suven-life-sciences-ltd) SUVEN · quiet · Most evidence points down · 64% evidence 33.1 out of 100 Growth Capital Valuation Relative
41. [Influx Healthtech Ltd](https://www.sectoralpha.in/stocks/influx-healthtech-ltd) INFLUX · quiet · Too little evidence to rank firmly · 42% evidence 49.7 out of 100 Growth Capital Valuation Relative
42. [Syncom Healthcare Ltd](https://www.sectoralpha.in/stocks/syncom-healthcare-ltd) SYNCOM · Too little evidence to rank firmly · 17% evidence 42.3 out of 100 Growth Capital Valuation Relative
43. [Indoco Remedies Ltd](https://www.sectoralpha.in/stocks/indoco-remedies-ltd) INDOCO · losing its lead · Too little evidence to rank firmly · 49% evidence 38.4 out of 100 Growth Capital Valuation Relative
44. [Sai Parenterals Ltd](https://www.sectoralpha.in/stocks/sai-parenterals-ltd) SAIPARENT · turning · Too little evidence to rank firmly · 31% evidence 36.7 out of 100 Growth Capital Valuation Relative

Missing figures are not scored as bad. They lower the confidence and pull the final score toward the middle. Relative strength counts only when the company has a reading for this week; with no reading, that factor is left out and its 20 points are shared across the other three in proportion. PEG is not shown when the ratio cannot mean anything: the company must be making a profit, its price-to-earnings must be positive, and its three-year earnings growth must fall between 5% and 60%. Dividing a price multiple by a loss, or by growth measured off a tiny base, produces a number that looks precise and tells you nothing. Under relative strength, one mark per week shows the last 12 weeks: a mark is filled where the company led NIFTY 500 by 5% or more over the 13 weeks ending that week, which is the same test used everywhere on this site. Price stage places the company on the same six-step path the industry is placed on (basing, turning, breaking out, leader, fading, asleep), read from how many weeks running it has led NIFTY 500 and whether that lead is growing or shrinking. It describes where the share price stands, not the direction of earnings, and it is not a recommendation; it is left blank for a company whose weekly history is too short or too stale to read. The figures in this ranking come from the industry comparison: results through the Sep 2026 quarter, and the P/E at that quarter's end. The sections above use the latest weekly price, so a P/E or return there can differ a little from the one here. The stage words in this ranking (such as losing its lead or breaking out) describe the lead over the index, not the price phase in the price section. Related companies: [Pharma - Formulators](https://www.sectoralpha.in/sectors/pharma-formulators), all 44 compared on one page. ## Which companies are close to Bafna Pharmaceuticals in size? Bafna Pharmaceuticals is the 38th largest of 44 Pharma - Formulators companies on Sector Alpha by market value (scores of 30 October 2026). Just above it: Accent Microcell, Amrutanjan Health Care and Bharat Parenterals. Just below it: Bajaj Healthcare, Lincoln Pharmaceuticals and Zim Laboratories. ### Pharma - Formulators companies close in size

1. [Accent Microcell Ltd](https://www.sectoralpha.in/stocks/accent-microcell-ltd) ₹1,533 crore
2. [Amrutanjan Health Care Ltd](https://www.sectoralpha.in/stocks/amrutanjan-health-care-ltd) ₹1,436 crore
3. [Bharat Parenterals Ltd](https://www.sectoralpha.in/stocks/bharat-parenterals-ltd) ₹1,399 crore
4. Bafna Pharmaceuticals Ltd ₹1,060 crore
5. [Bajaj Healthcare Ltd](https://www.sectoralpha.in/stocks/bajaj-healthcare-ltd) ₹1,031 crore
6. [Lincoln Pharmaceuticals Ltd](https://www.sectoralpha.in/stocks/lincoln-pharmaceuticals-ltd) ₹1,000 crore
7. [Zim Laboratories Ltd](https://www.sectoralpha.in/stocks/zim-laboratories-ltd) ₹731 crore

[All 44 Pharma - Formulators companies, largest first](https://www.sectoralpha.in/sectors/pharma-formulators#all-companies)

### Companies close in size in other industries

1. [Andhra Sugars Ltd](https://www.sectoralpha.in/stocks/andhra-sugars-ltd) ₹1,065 crore · Sugar
2. [Sula Vineyards Ltd](https://www.sectoralpha.in/stocks/sula-vineyards-ltd) ₹1,061 crore · Alcoholic Beverages
3. Bafna Pharmaceuticals Ltd ₹1,060 crore
4. [Pervasive Commodities Ltd](https://www.sectoralpha.in/stocks/pervasive-commodities-ltd) ₹1,060 crore · Trading
5. [Sahasra Electronic Solutions Ltd](https://www.sectoralpha.in/stocks/sahasra-electronic-solutions-ltd) ₹1,057 crore · Electronics - Others

## What else do people ask about Bafna Pharmaceuticals? ### What is Bafna Pharmaceuticals's share price today? Bafna Pharmaceuticals Ltd's share price is ₹430.20. The whole company is worth ₹1,018 Cr on the market. In the last 52 weeks it traded between ₹132 to ₹461; today it is 91% of the way up from the low, 75.9% above its 200-day average. The price has been rising for 25 weeks (as of 3 November 2026). ### What were Bafna Pharmaceuticals's latest quarterly results? Bafna Pharmaceuticals Ltd reported revenue of ₹26.6 Cr and net profit of ₹0.1 Cr for the Jun 2026 quarter. Revenue fell 23.2% and profit fell 97.6% compared with a year earlier. Earnings per share were ₹0.03. The operating margin was 3.4%, 11.3 percentage points lower than a year earlier (as of 3 November 2026). ### What is Bafna Pharmaceuticals's market cap? Bafna Pharmaceuticals Ltd's market capitalisation is ₹1,018 Cr at a share price of ₹430.20. Market cap is the share price times the number of shares, so it changes whenever the price moves (as of 3 November 2026). ### How is Bafna Pharmaceuticals performing? Bafna Pharmaceuticals Ltd's share price has been rising for 25 weeks. In its latest quarter, revenue fell 23.2% and profit fell 97.6% compared with a year earlier. Over the past 13 weeks it has done better than the NIFTY 500, for 12 weeks running (as of 3 November 2026). ### Is Bafna Pharmaceuticals in an uptrend? Yes, the price has been rising for 25 weeks (stage 2 of 4), 75.9% above its 200-day average, and 91% of the way up its 52-week range. A share price tends to move through four phases: moving sideways, rising, stalling and falling (as of 3 November 2026). ### Will Bafna Pharmaceuticals's share price go up? This page does not forecast Bafna Pharmaceuticals Ltd's share price. What it shows instead: the share price is ₹430.20, and it has been rising for 25 weeks. Its P/E of 130.6× is higher than 87% of its own last 9 years (as of 3 November 2026). ### Who owns Bafna Pharmaceuticals? Promoters own 75.0% of Bafna Pharmaceuticals Ltd, foreign institutions 9.3%, domestic institutions, and the public 15.7% (latest quarter). The biggest change over the last two years: Promoters cut their stake by 13.3 percentage points over 8 quarters (as of 3 November 2026). ### Where is Bafna Pharmaceuticals in its business cycle? Bafna Pharmaceuticals Ltd's FY26 operating margin was 11.0%, against a 15-year range of −77.0% to 15.0%: the middle of its own range, neither a peak nor a low. The latest quarter was 3.4%. Comparing margins with a company's own long history is a good way to see where it is in its cycle (as of 3 November 2026). ### What could break the Bafna Pharmaceuticals story? The main question: foreign institutions moved +9.3 percentage points over 8 quarters while the business went the other way. On price, this page treats a rise as over when the share price closes below its 200-day average on two Fridays in a row (as of 3 November 2026). ### Is Bafna Pharmaceuticals a stock worth studying right now? What the numbers show: Bafna Pharmaceuticals Ltd's share price, valuation and earnings point in different directions. The next one or two quarters should make it clearer. The main open question: whether the owners’ moves turn back in line with the business. Every number on this page is worked out by code from the published figures, with no forecasts and no price opinions (as of 3 November 2026). ## Lists

- Momentum stocks: https://www.sectoralpha.in/momentum-stocks-india
- Pharma stocks: https://www.sectoralpha.in/sectors/pharma-stocks-india

This is research, not advice. We’re not SEBI-registered.